From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

Accelerated Approval Program Virtual Public Meeting
The Accelerated Approval Pathway was created by Congress to allow patients with a serious or life-threatening disease earlier access to a potentially important treatment. At this virtual public meeting we explored the insights and lessons learned in the 30 years since its inception.
COVID-19 Evidence Accelerator: Therapeutics/Vaccines Lab Meeting
 02/17/2022 - 03:00 PM
COVID-19 Evidence Accelerator: Diagnostics Lab Meeting
This is the once-monthly COVID-19 Evidence Accelerator Diagnostics Lab Meeting. These meetings occur the third Thursday of every month at 12 pm ET. 
Real-World Data Webinar Series: Considerations for the Use of RWD and RWE
Real-World Data Webinar Series: Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products
Real-World Data Webinar Series: Registries
Real-World Data Webinar Series: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products
2021 Innovations in Regulatory Science Awards
The fifth annual Innovations in Regulatory Science Awards presented by the Reagan-Udall Foundation for the FDA will be held Tuesday, December 14, 2021
Real-World Data Webinar Series: Data Standards
  Real-World Data Webinar Series:
A Public Webinar Series on FDA-Issued Guidance on Real-World Evidence
A Public Webinar
A Practical Research Agenda for Treatment Development for Stimulant Use Disorder
A virtual public workshop to discuss a practical research agenda toward treatment development for stimulant use disorder. 
COVID-19 Lessons Learned: Clinical Evaluation of Therapeutics
COVID-19 Lessons Learned: Clinical Evaluation of Therapeutics